BEIJING, Aug. 11 Sinovac Biotech Ltd.(NYSE Amex: SVA), a leading provider of vaccines in China, today announcedthat it will host a conference call on Wednesday, August 19, 2009 at 8:00 a.m.ET to review the Company's second quarter financial results for the periodended June 30, 2009 and provide an update on recent corporate developments.
To access the conference call, please dial 1-877-407-4018 (USA) or1-201-689-8471 (international). A replay of the call will be available from11:00 a.m. ET on August 19, 2009 to September 2, 2009 at midnight. To accessthe replay, please dial 1-877-660-6853 (USA) or 1-201-612-7415 (international)and reference the account number 3055 and the access code 330444.
A live audio webcast of the call will also be available from the Investorssection on the corporate web site at http://www.sinovac.com . A webcast replaycan be accessed on the corporate website beginning August 19, 2009 and thereplay will remain available for 30 days.
Sinovac Biotech Ltd. is a China-based biopharmaceutical company thatfocuses on the research, development, manufacture and commercialization ofvaccines that protect against human infectious diseases. Sinovac'scommercialized vaccines include Healive(R) (hepatitis A), Bilive(R) (combinedhepatitis A and B), and Anflu(R) (influenza). Panflu(TM), Sinovac's pandemicinfluenza vaccine (H5N1), has already been approved for government stockpiling.Sinovac is developing vaccines for Enterovirus 71, Universal PandemicInfluenza, Japanese encephalitis vaccine, and Human Rabies vaccine. Itswholly-owned subsidiary, Tangshan Yian, is conducting field trials forindependently developed inactivated animal rabies vaccines.For more information, please contact: Contact Information: Helen G. Yang Sinovac Biotech Ltd. Phone: +86-10-8289-0088 x871 Fax: +86-10-6296-6910 Email: [email protected]
Investors: Amy Glynn/Sara Ephraim The Ruth Group Tel: +1-646-536-7023/7002 Email: [email protected] [email protected]
Media: Janine McCargo The Ruth Group Tel: +1-646-536-7033 Email: [email protected]
SOURCE Sinovac Biotech Ltd.